Intervention not reported
Overall survivala · adult women with symptoms of endometrial cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Disease‐free survivalb · adult women with symptoms of endometrial cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Delayed referralc · adult women with symptoms of endometrial cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Delayed presentationd · adult women with symptoms of endometrial cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Referral time (days)e · adult women with symptoms of endometrial cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Presentation time (days)f · adult women with symptoms of endometrial cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival (OS) · women with metastatic triple‐negative breast cancer (mTNBC)
Platinum showed no clear difference in overall survival (OS) compared with non‐platinum regimens (moderate certainty).
1 finding from 1 review
Intervention not reported
Treatment discontinuation due to adverse event (safety population) · women with metastatic triple‐negative breast cancer (mTNBC)
The intervention probably leads to lower treatment discontinuation due to adverse event (safety population) (moderate certainty).
1 finding from 1 review
Time to progression · women with metastatic triple‐negative breast cancer (mTNBC)
It is very uncertain whether platinum changes progression‐free survival/time to progression (PFS/TTP) compared with non‐platinum regimens (very low certainty).
1 finding from 1 review
Tumour response · women with metastatic triple‐negative breast cancer (mTNBC)
Platinum may leads to higher objective tumour response rate (OTRR) (assessable participants) compared with non‐platinum regimens (low certainty).
1 finding from 1 review
Intervention not reported
Treatment‐related death (safety population) · women with metastatic triple‐negative breast cancer (mTNBC)
The intervention may leads to higher treatment‐related death (safety population) (low certainty).
1 finding from 1 review
Intervention not reported
Nausea/vomiting* grade 3 or 4 (safety population) · women with metastatic triple‐negative breast cancer (mTNBC)
The intervention may leads to higher nausea/vomiting* grade 3 or 4 (safety population) (low certainty).
1 finding from 1 review
Intervention not reported
Nephrotoxicity (safety population) · women with metastatic triple‐negative breast cancer (mTNBC)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Anaemia grade 3 or 4 (safety population) · women with metastatic triple‐negative breast cancer (mTNBC)
The intervention may leads to higher anaemia grade 3 or 4 (safety population) (low certainty).
1 finding from 1 review
Intervention not reported
Hair loss (safety population) · women with metastatic triple‐negative breast cancer (mTNBC)
The intervention may leads to lower hair loss (safety population) (low certainty).
1 finding from 1 review
Intervention not reported
Leukopaenia (safety population) · women with metastatic triple‐negative breast cancer (mTNBC)
The intervention probably leads to higher leukopaenia (safety population) (moderate certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality · people with liver metastases
The intervention showed no clear difference in all‐cause mortality (low certainty).
1 finding from 1 review
Intervention not reported
Cancer mortality · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
All adverse events and complications · people with liver metastases
The intervention led to higher all adverse events and complications; GRADE not reported.
1 finding from 1 review
Intervention not reported
Health‐related quality of life · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review